Three of Ver­tex’s islet cell ther­a­py pa­tients go in­sulin-in­de­pen­dent

OR­LAN­DO — Ver­tex Phar­ma­ceu­ti­cals said a third pa­tient in a Phase 1/2 tri­al as­sess­ing its islet cell ther­a­py as a treat­ment for type 1 di­a­betes …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.